Design Therapeutics, Inc. (DSGN)Healthcare | Biotechnology | Carlsbad, United States | NasdaqGS
15.11 USD
-0.14
(-0.918%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 15.11 |
Hot Take ↕ | Aug. 22, 2026, 3:47 a.m. EDT
The immediate outlook is fraught with danger due to a severe disconnect between the company's deteriorating fundamentals and its recent price performance. While the stock has rallied recently, the underlying business is bleeding cash with negative free cash flow and a negative return on equity, leaving it reliant on capital markets rather than organic growth. This fragility is starkly highlighted by the options market, where traders are buying deep out-of-the-money puts, betting on a sharp correction or failure of the latest clinical data to translate into value. The recent price surge appears to be a speculative bubble fueled by hope rather than financial reality, making this a high-risk environment for near-term entries. Looking further ahead, the long-term picture remains murky; despite a recent year-over-year price gain, the company has suffered a catastrophic 90% decline over the last few years, and the lack of a dividend or cash generation suggests investors are waiting for a miracle cure or a successful acquisition rather than steady compounding. Until the balance sheet stabilizes and consistent profitability is demonstrated, this remains a speculative vehicle unsuitable for core portfolios. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.173450 |
| MSTL | 0.190267 |
| AutoARIMA | 0.197836 |
| AutoETS | 0.197838 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 1.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.256 |
| Excess Kurtosis | -1.18 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.319 |
| Market Cap | 945,608,768 |
| Forward P/E | -9.49 |
| Beta | 1.64 |
| Website | https://www.designtx.com |
As of Aug. 22, 2026, 3:47 a.m. EDT: Speculators are aggressively positioning for a downside event in the immediate term, evidenced by massive open interest in deep out-of-the-money puts (strikes 3.0 and 6.0) relative to volume, suggesting a 'pin risk' or crash scenario is priced in for the August expiration. Conversely, there is significant long-dated call open interest at strikes 25.0 and 17.0, indicating a speculative belief in a potential multi-year recovery or binary event-driven rally, while near-term call activity remains thin.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.6614311 |
| Address1 | 6,005 Hidden Valley Road |
| Address2 | Suite 110 |
| All Time High | 43.0 |
| All Time Low | 1.94 |
| Ask | 19.02 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 561,600 |
| Average Daily Volume3 Month | 706,887 |
| Average Volume | 706,887 |
| Average Volume10Days | 561,600 |
| Beta | 1.639 |
| Bid | 15.18 |
| Bid Size | 1 |
| Board Risk | 10 |
| Book Value | 3.226 |
| City | Carlsbad |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 15.11 |
| Current Ratio | 18.862 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 15.36 |
| Day Low | 14.8 |
| Debt To Equity | 1.319 |
| Display Name | Design Therapeutics |
| Earnings Timestamp | 1,785,760,200 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -78,344,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -9.569 |
| Enterprise Value | 749,636,160 |
| Eps Current Year | -1.36286 |
| Eps Forward | -1.59286 |
| Eps Trailing Twelve Months | -1.18 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.8297 |
| Fifty Day Average Change | 1.2802992 |
| Fifty Day Average Change Percent | 0.092576064 |
| Fifty Two Week Change Percent | 166.14311 |
| Fifty Two Week High | 17.25 |
| Fifty Two Week High Change | -2.1400003 |
| Fifty Two Week High Change Percent | -0.12405799 |
| Fifty Two Week Low | 5.28 |
| Fifty Two Week Low Change | 9.83 |
| Fifty Two Week Low Change Percent | 1.8617424 |
| Fifty Two Week Range | 5.28 - 17.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,617,024,600,000 |
| Float Shares | 36,193,472 |
| Forward Eps | -1.59286 |
| Forward P E | -9.486081 |
| Free Cashflow | -32,364,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 55 |
| Fullday Change | -0.14 |
| Fullday Change Percent | -0.918035 |
| Fullday Price | 15.11 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -58,781,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.31867 |
| Held Percent Institutions | 0.78578 |
| Implied Shares Outstanding | 62,581,651 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-03-26 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California. |
| Long Name | Design Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 945,608,768 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_625814292 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -70,795,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 954,370,177 |
| Number Of Analyst Opinions | 6 |
| Open | 15.12 |
| Operating Cashflow | -55,083,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 858 293 4900 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 15.11 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 15.25 |
| Price Eps Current Year | -11.086979 |
| Price Hint | 2 |
| Price To Book | 4.683819 |
| Profit Margins | 0.0 |
| Quick Ratio | 18.61 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.14 |
| Regular Market Change Percent | -0.918035 |
| Regular Market Day High | 15.36 |
| Regular Market Day Low | 14.8 |
| Regular Market Day Range | 14.8 - 15.36 |
| Regular Market Open | 15.12 |
| Regular Market Previous Close | 15.25 |
| Regular Market Price | 15.11 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 820,754 |
| Return On Assets | -0.22534001 |
| Return On Equity | -0.34127 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 62,581,651 |
| Shares Percent Shares Out | 0.0947 |
| Shares Short | 5,925,557 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,669,571 |
| Short Name | Design Therapeutics, Inc. |
| Short Percent Of Float | 0.1254 |
| Short Ratio | 12.98 |
| Source Interval | 15 |
| State | CA |
| Symbol | DSGN |
| Target High Price | 22.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 21.0 |
| Target Median Price | 21.0 |
| Total Cash | 207,396,000 |
| Total Cash Per Share | 3.314 |
| Total Debt | 2,662,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.18 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.409775 |
| Two Hundred Day Average Change | 3.7002249 |
| Two Hundred Day Average Change Percent | 0.32430306 |
| Type Disp | Equity |
| Volume | 820,754 |
| Website | https://www.designtx.com |
| Zip | 92,011 |